A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

This is an open-label, multicenter Phase 1b/2 study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in adult patients with selected advanced solid tumors (Part A/Phase 1b); and to estimate the efficacy of the combination in three separate cohorts: 1) patients with advanced solid tumors that have progressed on prior PD-1/PD-L1inhibitors, 2) patients with platinum-resistant ovarian cancer and 3) patients with pancreatic ductal adenocarcinoma (Phase 2).

Key facts

Study ID

NCT02880371

Run by

Pfizer

People needed

82

Starts

2016-09-01

Expected to finish

2019-10-24

Last updated by the study team

2022-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Ronald Reagan UCLA Medical Center — Los Angeles, California, United States
• UCLA Hematology/Oncology — Los Angeles, California, United States
• UCLA Hematology/Oncology - Santa Monica — Santa Monica, California, United States
• University of Colorado Denver — Aurora, Colorado, United States
• University of Colorado Hospital — Aurora, Colorado, United States
• Hem-Onc Associates of Treasure Coast — Port Saint Lucie, Florida, United States
• Parkview Cancer Institute — Fort Wayne, Indiana, United States
• Parkview Regional Medical Center — Fort Wayne, Indiana, United States
• Parkview Research Center — Fort Wayne, Indiana, United States
• PPG — Fort Wayne, Indiana, United States
• Horizon Oncology Research, Inc. — Lafayette, Indiana, United States
• Hall-Perrine Cancer Center Laboratory — Cedar Rapids, Iowa, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Mayo Clinic Labs - Rochester Superior — Rochester, Minnesota, United States
• Regions Cancer Care Center — Saint Paul, Minnesota, United States
• Regions Hospital Pharmacy — Saint Paul, Minnesota, United States
• Regions Hospital — Saint Paul, Minnesota, United States
• HealthPartners Neurosciences Center — Saint Paul, Minnesota, United States
• Tennessee Oncology PLLC — Nashville, Tennessee, United States
• Tennessee Oncology, PLLC — Nashville, Tennessee, United States
• The Sarah Cannon Research Institute — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.